NCT04164199 2026-04-14Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesBeOne MedicinesPhase 3 Active not recruiting404 enrolled
NCT03233139 2026-02-12Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced MalignanciesRegeneron PharmaceuticalsPhase 1 Active not recruiting146 enrolled